Pharmafile Logo
Pharmafocus logo
Advanced Search

Eli Lilly

Showing 15 posts of 218 posts found.

lilly_entrance_web

Lilly dumps Hanmi’s rheumatoid arthritis med

February 20, 2018
Manufacturing and Production, Sales and Marketing Eli Lilly, arthritis, hanmi, pharma

Eli Lilly and Hanmi signed an exclusive licensing and collaboration agreement to develop the Bruton’s tyrosine kinase (BTK) inhibitor, HM71224, …

News

Lilly posts promising P3 Taltz data

February 14, 2018
Research and Development Cosentyx, Eli Lilly, IL-17, Novartis, Taltz, biotech, drugs, pharma, pharmaceutical

The IL-17 market is a crowded space, and one dominated by Novartis’ Cosentyx. Eli Lilly is attempting to challenge that, …

News
david_kendall

MannKind entices Lilly VP to CMO role

February 9, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Eli Lilly, Mannkind, biotech, drugs, pharma, pharmaceutical

MannKind, the California-based biotech, announced that David Kendall would be joining its team as Chief Medical Officer and would be …

Appointment
alex_azar_wwsg_photo_cropped

Trump nominee and ex-Lilly exec confirmed as US Health Secretary by Senate

January 25, 2018
Manufacturing and Production, Medical Communications, Sales and Marketing Alex Azar, Eli Lilly, President trump, Trump, US, pharma

Alex Azar, President’s Trump’s controversial pick for Health and Human Services Secretary (HHS), has been confirmed in the role after …

News
lilly_entrance_web

Eli Lilly’s Taltz get EU approval in psoriatic arthritis subgroup

January 24, 2018
Research and Development, Sales and Marketing EU, Eli Lilly, Europe, European Commission, Taltz, pharma, psoriatic arthritis

Eli Lilly has revealed that its IgG4 monoclonal antibody Taltz (ixekizumab) has been awarded marketing approval from the European Commission …

News
lilly_entrance_web

Cyramza fails to improve overall survival in gastric cancer, Lilly scraps regulatory plans

December 11, 2017
Research and Development, Sales and Marketing Cancer, Eli Lilly, cyramza, gastric cancer, pharma

Eli Lilly has unveiled Phase 3 results which reveal that its VEGF Receptor 2 antagonist Cyramza (ramucirumab) met its primary …

News

Sanofi launches patent infringement lawsuit against Mylan over diabetes pen

October 25, 2017
Research and Development, Sales and Marketing Basaglar, Eli Lilly, Lantus, Mylan, Sanofi, diabetes, insulin, patent infringement, pharma

Sanofi has launched a lawsuit against Mylan as part of a dispute that alleges that the latter infringed upon 18 …

News
lilly2_web

Lilly looks to leave behind animal health business

October 25, 2017
Research and Development, Sales and Marketing Elanco, Eli Lilly, biotech, drugs, pharma, pharmaceutical

Eli Lilly released its Q3 financials and the major talking point was the announcement that the business was reviewing “strategic …

News
lilly_entrance_web

Lilly teams up with CureVac in $1.8 billion cancer vaccine partnership

October 19, 2017
Research and Development, Sales and Marketing Cancer, CureVac, Eli Lilly, Vaccine

Eli Lilly has announced it is to partner up with CureVac to leverage its proprietary RNActive technology in order to …

News
lilly_logo_2

Lilly reveals major senior leadership reshuffle

October 2, 2017
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Eli Lilly, biotech, drugs, pharma, pharmaceutical

Eli Lilly revealed on 29 September that it would promote four staff members to senior staff positions, and two senior …

Appointment
lilly2_web

Lilly receives FDA breast cancer pill approval, doubts remain

September 29, 2017
Medical Communications, Sales and Marketing Eli Lilly, Verzenio, biotech, drugs, pharma, pharmaceutical

Eli Lilly has received an important approval for its breast cancer treatment, Verzenio. The drug will be the third to …

News
4420456374_64a3d7e6aa

Top Ten most popular articles on Pharmafile.com this week

September 15, 2017
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Cosentyx, Eli Lilly, Martin Skreli, Teva, pharma, top ten

This week has been a particularly eventful one for the industry: among our top stories, Martin Shkreli finally heads to …

News

Lilly’s Cyramza combo boasts strong results in bladder cancer

September 11, 2017
Research and Development, Sales and Marketing Eli Lilly, bladder cancer, cyramza, immunotherapy, pharma

Eli Lilly has announced new Phase 3 data at the European Society for Medical Oncology 2017 Congress which further add …

News
gavel

Patently problematic? The impact of the Eli Lilly/Actavis intellectual property battle

September 4, 2017
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Actavis, Eli Lilly, biotech, drugs, pemetrexed, pharma, pharmaceutical

The UK Supreme Court has sent shockwaves through the intellectual property world with its recent decision on Eli Lilly v …

Feature
lilly2_web

Lilly gets second shot at application for ‘blockbuster’ arthritis drug

August 31, 2017
Sales and Marketing Eli Lilly, arthritis, baricitinib, biotech, drugs, pharma, pharmaceutical

Earlier this year, Eli Lilly was on the receiving end of one of the most surprising setbacks in recent times …

News
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025